"Enzyme Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
| Descriptor ID |
D004791
|
| MeSH Number(s) |
D27.505.519.389
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Inhibitors".
This graph shows the total number of publications written about "Enzyme Inhibitors" by people in this website by year, and whether "Enzyme Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 0 | 2 |
| 1996 | 0 | 5 | 5 |
| 1997 | 2 | 5 | 7 |
| 1998 | 2 | 2 | 4 |
| 1999 | 5 | 4 | 9 |
| 2000 | 3 | 3 | 6 |
| 2001 | 1 | 11 | 12 |
| 2002 | 4 | 11 | 15 |
| 2003 | 1 | 9 | 10 |
| 2004 | 2 | 9 | 11 |
| 2005 | 3 | 4 | 7 |
| 2006 | 4 | 5 | 9 |
| 2007 | 3 | 9 | 12 |
| 2008 | 2 | 9 | 11 |
| 2009 | 6 | 3 | 9 |
| 2010 | 2 | 4 | 6 |
| 2011 | 2 | 5 | 7 |
| 2012 | 2 | 2 | 4 |
| 2013 | 5 | 8 | 13 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 4 | 6 |
| 2016 | 3 | 1 | 4 |
| 2017 | 2 | 3 | 5 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 2 | 7 |
| 2020 | 6 | 2 | 8 |
| 2021 | 3 | 0 | 3 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Enzyme Inhibitors" by people in Profiles.
-
3D-QSAR and scaffold hopping based designing of benzo[d]ox-azol-2(3H)-one and 2-oxazolo[4,5-b]pyridin-2(3H)-one derivatives as selective aldehyde dehydrogenase 1A1 inhibitors: Synthesis and biological evaluation. Arch Pharm (Weinheim). 2022 Sep; 355(9):e2200108.
-
Pharmacological Inhibition of Inositol-Requiring Enzyme 1a RNase Activity Protects Pancreatic Beta Cell and Improves Diabetic Condition in Insulin Mutation-Induced Diabetes. Front Endocrinol (Lausanne). 2021; 12:749879.
-
Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
-
Kinetic, spectral, and structural studies of the slow-binding inhibition of the Escherichia coli dihydrodipicolinate synthase by 2, 4-oxo-pentanoic acid. Arch Biochem Biophys. 2021 05 15; 702:108819.
-
Crystal structures of glutathione- and inhibitor-bound human GGT1: critical interactions within the cysteinylglycine binding site. J Biol Chem. 2021 Jan-Jun; 296:100066.
-
Identification of Small-Molecule Inhibitors of Neutral Ceramidase (nCDase) via Target-Based High-Throughput Screening. SLAS Discov. 2021 01; 26(1):113-121.
-
Triple-Negative Breast Cancer Cells Exhibit Differential Sensitivity to Cardenolides from Calotropis gigantea. J Nat Prod. 2020 07 24; 83(7):2269-2280.
-
Addressing selectivity issues of aldose reductase 2 inhibitors for the management of diabetic complications. Future Med Chem. 2020 07; 12(14):1327-1358.
-
SAR of non-hydrolysable analogs of pyridoxal 5'-phosphate against low molecular weight protein tyrosine phosphatase isoforms. Bioorg Med Chem Lett. 2020 08 15; 30(16):127342.
-
Inhibitor design to target a unique feature in the folate pocket of Staphylococcus aureus dihydrofolate reductase. Eur J Med Chem. 2020 Aug 15; 200:112412.